- Novo Nordisk Shares Slump After Ozempic Pill Fails in Alzheimer’s Trials The Wall Street Journal
- Novo Nordisk shares plunge to four-year low after Alzheimer’s drug trial fails to hit key target CNBC
- Novo Nordisk shares drop after Alzheimer’s trial misses main goal Yahoo Finance
- Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says CNN
- Weight-loss drugs: What other conditions are they being used and tested for? Reuters